Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum CCFM16
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum CCFM16 is a specific probiotic bacterial strain belonging to the Bifidobacterium genus, identified and maintained by Jiangnan University's Culture Collection of Food Microorganisms (CCFM). It is primarily investigated as a live biotherapeutic product for the treatment of inflammatory and allergic conditions, specifically atopic dermatitis (AD). The strain functions by modulating the host's intestinal microbiota, where it has been shown to increase microbial alpha diversity and the proportion of Bacteroidetes while reducing the Firmicutes/Bacteroidetes (F/B) ratio. These microbial shifts are intended to restore intestinal homeostasis and regulate systemic immune responses to alleviate clinical symptoms of AD. In clinical trials, while CCFM16 demonstrated significant effects on gut microbiota composition, its impact on clinical severity indices like the SCORAD score has been reported as less pronounced compared to other strains such as Lactobacillus plantarum CCFM8610.
- Other names
- 两歧双歧杆菌CCFM16Bifidobacterium bifidum strain CCFM16B. bifidum CCFM16
Beyond the preview
Go deeper on bifidobacterium bifidum CCFM16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum CCFM16.